AstraZeneca could receive up to $400 million from Takeda after approaching the company to jointly develop and market a new treatment for Parkinson’s disease (PD).
Parkinson’s UK and the University of Sheffield have launched a groundbreaking ‘virtual biotech’ company to develop new treatments for Parkinson’s disease.
